Based on the SymBio Pharmaceuticals Ltd stock forecast from 0 analysts, the average analyst target price for SymBio Pharmaceuticals Ltd is not available over the next 12 months. SymBio Pharmaceuticals Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of SymBio Pharmaceuticals Ltd is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, SymBio Pharmaceuticals Ltd’s stock price was JPY 210.00. SymBio Pharmaceuticals Ltd’s stock price has changed by -5.41% over the past week, -11.76% over the past month and -14.29% over the last year.
No recent analyst target price found for SymBio Pharmaceuticals Ltd
No recent average analyst rating found for SymBio Pharmaceuticals Ltd
Company Overview SymBio Pharmaceuticals Ltd
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS. In addition, it is involved in the development SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan. Read Less
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is mar...Read More
Frequently Asked Questions About SymBio Pharmaceuticals Ltd (4582:TSE) Stock
Stock Target Advisor's fundamental analysis for SymBio Pharmaceuticals Ltd's stock is Bearish.
Unfortunately we do not have enough data on 4582:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4582:TSE's stock to indicate what its average analyst target is.
4582:TSE stock's Price/Earning ratio is 14.68.
Our analysis grades 4582:TSE stock's Price / Earning ratio at F. This means that 4582:TSE stock's Price/Earning ratio is above 46% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4582:TSE may be fairly valued for its sector
The last closing price of 4582:TSE's stock was JPY 210.00.
The most recent market capitalization for 4582:TSE is JPY 11.09B.
Unfortunately we do not have enough analyst data on 4582:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains SymBio Pharmaceuticals Ltd's stock.
As per our most recent records SymBio Pharmaceuticals Ltd has 109 Employees.
SymBio Pharmaceuticals Ltd's registered address is Toranomon 30 Mori Building, Tokyo, Japan, 105-0001.
You can get more information about it from SymBio Pharmaceuticals Ltd's website at https://www.symbiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About SymBio Pharmaceuticals Ltd (4582:TSE) Stock
Stock Target Advisor's fundamental analysis for SymBio Pharmaceuticals Ltd's stock is Bearish.
Unfortunately we do not have enough data on 4582:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4582:TSE's stock to indicate what its average analyst target is.
4582:TSE stock's Price/Earning ratio is 14.68.
Our analysis grades 4582:TSE stock's Price / Earning ratio at F. This means that 4582:TSE stock's Price/Earning ratio is above 46% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4582:TSE may be fairly valued for its sector
The last closing price of 4582:TSE's stock was JPY 210.00.
The most recent market capitalization for 4582:TSE is JPY 11.09B.
Unfortunately we do not have enough analyst data on 4582:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains SymBio Pharmaceuticals Ltd's stock.
As per our most recent records SymBio Pharmaceuticals Ltd has 109 Employees.
SymBio Pharmaceuticals Ltd's registered address is Toranomon 30 Mori Building, Tokyo, Japan, 105-0001.
You can get more information about it from SymBio Pharmaceuticals Ltd's website at https://www.symbiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4582:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
